ACADIA Pharmaceuticals IncNASDAQ:ACAD
- LAST PRICE14.7900
- TODAY'S CHANGE (%)0.1700 (1.1628%)
- Bid / Lots14.7800/ 2
- Ask / Lots14.8000/ 6
- Open / Previous Close14.7450 / 14.6200
- Day Range
- 52 Week Range
- Volume697,306
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACAD |
|---|---|---|
| 09:32 ET | 15268 | 14.52 |
| 09:33 ET | 1738 | 14.5 |
| 09:35 ET | 4670 | 14.55 |
| 09:37 ET | 1300 | 14.52 |
| 09:39 ET | 2700 | 14.54 |
| 09:42 ET | 1300 | 14.62 |
| 09:44 ET | 5502 | 14.59 |
| 09:46 ET | 1111 | 14.63 |
| 09:48 ET | 1335 | 14.6 |
| 09:50 ET | 30731 | 14.5 |
| 09:51 ET | 30757 | 14.49 |
| 09:53 ET | 16800 | 14.56 |
| 09:55 ET | 8949 | 14.5 |
| 09:57 ET | 9919 | 14.45 |
| 10:00 ET | 22656 | 14.49 |
| 10:02 ET | 9324 | 14.45 |
| 10:04 ET | 3173 | 14.47 |
| 10:06 ET | 13378 | 14.47 |
| 10:08 ET | 4849 | 14.43 |
| 10:09 ET | 9484 | 14.46 |
| 10:11 ET | 350 | 14.46 |
| 10:13 ET | 2510 | 14.45 |
| 10:15 ET | 10670 | 14.46 |
| 10:18 ET | 2010 | 14.45 |
| 10:20 ET | 767 | 14.43 |
| 10:22 ET | 2604 | 14.43 |
| 10:24 ET | 6008 | 14.455 |
| 10:26 ET | 9202 | 14.45 |
| 10:27 ET | 3443 | 14.45 |
| 10:29 ET | 1469 | 14.45 |
| 10:31 ET | 3886 | 14.45 |
| 10:33 ET | 6087 | 14.46 |
| 10:36 ET | 3205 | 14.45 |
| 10:38 ET | 1910 | 14.44 |
| 10:40 ET | 12559 | 14.46 |
| 10:42 ET | 5442 | 14.42 |
| 10:44 ET | 21963 | 14.465 |
| 10:45 ET | 5130 | 14.49 |
| 10:47 ET | 21438 | 14.495 |
| 10:49 ET | 8291 | 14.46 |
| 10:51 ET | 31988 | 14.48 |
| 10:54 ET | 7766 | 14.4542 |
| 10:56 ET | 6195 | 14.45 |
| 10:58 ET | 10496 | 14.455 |
| 11:00 ET | 14176 | 14.56 |
| 11:02 ET | 4239 | 14.58 |
| 11:03 ET | 3737 | 14.62 |
| 11:05 ET | 1663 | 14.68 |
| 11:07 ET | 4690 | 14.68 |
| 11:09 ET | 11600 | 14.67 |
| 11:12 ET | 600 | 14.68 |
| 11:14 ET | 6472 | 14.6 |
| 11:16 ET | 2443 | 14.58 |
| 11:18 ET | 13425 | 14.59 |
| 11:20 ET | 5550 | 14.62 |
| 11:21 ET | 6601 | 14.64 |
| 11:23 ET | 9147 | 14.67 |
| 11:25 ET | 1619 | 14.67 |
| 11:27 ET | 6167 | 14.68 |
| 11:30 ET | 4645 | 14.6999 |
| 11:32 ET | 2961 | 14.74 |
| 11:34 ET | 2002 | 14.74 |
| 11:36 ET | 1614 | 14.715 |
| 11:38 ET | 5554 | 14.72 |
| 11:39 ET | 1600 | 14.75 |
| 11:41 ET | 2100 | 14.735 |
| 11:43 ET | 3272 | 14.73 |
| 11:45 ET | 2543 | 14.74 |
| 11:48 ET | 1460 | 14.745 |
| 11:50 ET | 1000 | 14.75 |
| 11:52 ET | 7600 | 14.73 |
| 11:54 ET | 3983 | 14.725 |
| 11:56 ET | 5514 | 14.72 |
| 11:57 ET | 1100 | 14.72 |
| 11:59 ET | 1889 | 14.705 |
| 12:01 ET | 1461 | 14.67 |
| 12:03 ET | 1775 | 14.67 |
| 12:06 ET | 2000 | 14.675 |
| 12:08 ET | 1192 | 14.676 |
| 12:10 ET | 600 | 14.675 |
| 12:12 ET | 3200 | 14.675 |
| 12:14 ET | 3684 | 14.675 |
| 12:15 ET | 6448 | 14.695 |
| 12:17 ET | 4377 | 14.73 |
| 12:19 ET | 3706 | 14.75 |
| 12:21 ET | 5272 | 14.78 |
| 12:24 ET | 1306 | 14.79 |
Oct 17, 2024
Press Release: Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024, from 6:46PM ET on Thursday Oct 17, 2024 by Dow Jones
6:46PM ET on Thursday Oct 17, 2024 by Dow JonesAcadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024, from 6:41PM ET on Thursday Oct 17, 2024 by Dow Jones
6:41PM ET on Thursday Oct 17, 2024 by Dow Jones
Oct 16, 2024
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE(TM) (trofinetide) for the Treatment of Rett Syndrome, from 4:07PM ET on Wednesday Oct 16, 2024 by Dow Jones
4:07PM ET on Wednesday Oct 16, 2024 by Dow Jones
Oct 8, 2024
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Tuesday Oct 08, 2024 by Dow Jones
4:05PM ET on Tuesday Oct 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ACADIA Pharmaceuticals Inc | 2.4B | 81.6x | --- |
Azenta Inc | 2.2B | -16.0x | --- |
Catalyst Pharmaceuticals Inc | 2.6B | 40.7x | --- |
Veracyte Inc | 2.7B | -48.0x | --- |
Novavax Inc | 1.5B | -3.3x | --- |
Beam Therapeutics Inc | 2.0B | -13.7x | --- |
Company Information
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Contact Information
- Headquarters
- 12830 El Camino Real, Suite 400SAN DIEGO, CA, United States 92130
- Phone
- 858-558-2871
- Fax
- 858-558-2872
Executives
- Independent Chairman of the Board
- Stephen Biggar
- Chief Executive Officer, Director
- Catherine Owen Adams
- Chief Financial Officer, Executive Vice President
- Mark Schneyer
- Chief Operating Officer, Executive Vice President, Head of Commercial
- Brendan Teehan
- Executive Vice President, Company Secretary and Chief Legal Officer
- Jennifer Rhodes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
|---|---|
Revenue (TTM) | $890.5M |
Shares Outstanding | 165.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.37 |
EPS | $0.18 |
Book Value | $2.62 |
P/E Ratio | 81.6x |
Price/Sales (TTM) | 2.7 |
Price/Cash Flow (TTM) | 57.7x |
Operating Margin | 2.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
